Neurocrine Biosciences NBIX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.86B+21.4% | $2.36B+24.8% | $1.89B+26.8% | $1.49B+31.3% | ||
| $52.1M+53.2% | $34M-14.4% | $39.7M+71.1% | $23.2M+62.2% | ||
| $2.81B+21.0% | $2.32B+25.7% | $1.85B+26.1% | $1.47B+30.9% | ||
| 98.2%-0.4pp | 98.6%+0.7pp | 97.9%-0.5pp | 98.4%-0.3pp | ||
| $1.02B+38.9% | $731.1M+29.4% | $565M+21.8% | $463.8M+41.4% | ||
| $1.16B+14.8% | $1.01B+13.5% | $887.6M+17.9% | $752.7M+29.0% | ||
| $2.24B+25.6% | $1.78B+9.1% | $1.64B+32.0% | $1.24B+20.2% | ||
| $619.1M+8.5% | $570.5M+127% | $250.9M+0.8% | $249M— | ||
| 21.6%-2.6pp | 24.2%+10.9pp | 13.3%-3.4pp | 16.7%— | ||
| $86.3M— | —— | $81.2M— | —— | ||
| —— | —— | —— | —— | ||
| $705.4M+45.1% | $486M+46.3% | $332.1M+55.3% | $213.9M— | ||
| $226.8M+56.7% | $144.7M+75.6% | $82.4M+38.7% | $59.4M— | ||
| $478.6M+40.2% | $341.3M+36.7% | $249.7M+61.6% | $154.5M+59.4% | ||
| 16.7%+2.2pp | 14.5%+1.3pp | 13.2%+2.9pp | 10.4%+1.8pp | ||
| $4.66+41.6% | $3.29+34.8% | $2.44+58.4% | $1.54+55.6% | ||
| $4.82+42.6% | $3.38+32.5% | $2.55+58.4% | $1.61+56.3% | ||
| 408.5M-1.7% | 415.5M+4.0% | 399.4M+2.1% | 391.1M-0.1% | ||
| 397.6M-1.1% | 402.1M+3.0% | 390.3M+2.0% | 382.5M+1.2% | ||
| —— | -$37.1M-231% | $28.4M-7.8% | $30.8M+47.4% | ||
| $90.3M-0.8% | $91M+68.8% | $53.9M+1,215% | $4.1M+7.9% | ||
| $485.9M+42.9% | $340.1M+28.5% | $264.6M+78.4% | $148.3M— | ||
| $26M+10.6% | $23.5M+32.0% | $17.8M+17.9% | $15.1M+38.5% | ||
| —— | —— | —— | —— | ||
| $81.4M-62.6% | $217.5M+322% | $51.5M+258% | $14.4M— | ||
| $160.2M+269% | $43.4M— | —— | $114.6M+102% | ||
| —— | $41.8M-55.3% | $93.5M-42.4% | $162.2M+471% | ||
| $15.3M-19.9% | $19.1M— | —— | —— | ||
| $3.5M+3,600% | -$100K-101% | $12.5M— | —— | ||
| $36.4M-4.7% | $38.2M+35.0% | $28.3M— | —— | ||
| $129.4M+6.0% | $122.1M+87.0% | $65.3M+46.1% | $44.7M+62.5% | ||
| $17.4M+39.2% | $12.5M-91.3% | $143.9M— | $0-100% | ||
| $1.02B+38.9% | $731.1M+29.4% | $565M+21.8% | $463.8M+41.4% | ||
| $2.86B+21.4% | $2.36B+24.8% | $1.89B+26.8% | $1.49B+31.3% | ||
| $217.9M+11.5% | $195.5M+0.6% | $194.3M+12.2% | $173.1M+29.0% | ||
| $649.2M+8.6% | $597.6M+120% | $272.2M+2.9% | $264.6M— | ||
| 22.7%-2.7pp | 25.4%+10.9pp | 14.4%-3.3pp | 17.8%— | ||
| $619.1M+8.5% | $570.5M+127% | $250.9M+0.8% | $249M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.1B in revenue over the trailing twelve months, up 28.6% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $668.6M in net income over the trailing twelve months, a 21.6% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.2% and operating margin is 25.4%, with a 21.6% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.49.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
